Applied DNA Schedules Fiscal 2021 First Quarter Financial Results Conference Call and Webcast for Thursday, February 11, 2021
02/05/2021 - 07:00 AM
Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar ’ section of the Company’s corporate website and embedded into the live webcast.
Conference Call and Webcast Information - Live
Date:
Thursday, February 11, 2021, at 4:30 p.m. Eastern Daylight Time
Dial in:
844-887-9402
412-317-6798 (international)
Conference ID: 10151013
Hosts:
Dr. James A. Hayward, chairman, president, and CEO
Beth Jantzen, chief financial officer
Judith Murrah, chief operating officer
Webcast:
https://services.choruscall.com/links/apdn210211.html
Conference Call and Webcast Information - Replay
A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call.
The webcast and accompanying PowerPoint presentation will also be archived on the ‘IR Calendar ’ page listed under the Investor Relations drop-down menu on the Company’s website .
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn . Join our mailing list .
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN’, and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020, and other reports we file with the SEC, which are available at www.sec.gov . Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210205005069/en/
APDN Rankings
#4756 Ranked by Stock Gains
APDN Stock Data
Industry
Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Sector
Manufacturing
Tags
Information Technology Services, Pharmaceuticals: Major, Technology Services, Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing , Miscellaneous Commercial Services, Commercial Services, Manufacturing, Health Technology
Country
US
City
Stony Brook
About APDN
we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.